The Pharmacogenetics Core is responsible for correlating outcome observations (toxicity, efficacy, survival, PK/PD) with genetic variants (germline or somatic) to identify key genetic determinants and biomarkers that predict response to specific treatments. We also evaluate the impact of genetic variants on drug metabolism, transport, and molecular targets that influence drug resistance or contribute to inter-individual variation in therapeutic outcomes.
Facility Head: William Douglas Figg, Sr., Pharm.D.
Address: Building 10, Room 5A01, Bethesda
The Pharmacogenetics Core is open to all NCI intramural clinical investigators.